This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary>Once-daily methylphenidate receives approval Aug. 1 for pediatric attention deficit/hyperactivity disorder. Concerta is slated for an August launch, coinciding with the start of the school year, according to Alza and co-marketing partner McNeil Consumer Healthcare. A combined sales force of 520 reps will promote Concerta. The product will be launched at a wholesale acquisition cost of $1.75 per tablet for the 18 mg dose and $1.85 per tablet for the 36 mg dose, which represents a 71¢ to 81¢ discount to the daily cost of Novartis' twice-daily Ritalin-SR
You may also be interested in...
Biodegradable plastic alternatives for use in cosmetic products were left unaddressed, and thus arguably unusable, under the US Microbead-Free Waters Act enacted in late 2015. European industry stakeholders now face the prospect of a far more extensive microplastic ban, and the viability of bioplastics to replace conventional, petroleum-based microplastics is an area in need of work.
Most of the foreign OTC drug firms targeted in latest warnings FDA published, including the GUM oral care brand manufacturer, were placed on import alert due to GMP violations. Each was inspected by FDA during June, July or May 2019, when the agency was wrapping up an initiative to inspect all previously uninspected drug manufacturers.
AstraZeneca will reacquire Allergan's investigational IL-23 inhibitor brazikumab, and Nestle is to buy its GI drug Zenpep, which had nine-month revenue of $208m.